Rohto Pharmaceutical Co.L... (RPHCF)
Rohto Pharmaceutical Statistics
Share Statistics
Rohto Pharmaceutical has 228.14M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 228.14M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 171.73M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 22.91 and the forward PE ratio is null. Rohto Pharmaceutical's PEG ratio is 0.
| PE Ratio | 22.91 |
| Forward PE | n/a |
| PS Ratio | 2.62 |
| Forward PS | n/a |
| PB Ratio | 2.88 |
| P/FCF Ratio | 27.98 |
| PEG Ratio | 0 |
Enterprise Valuation
Rohto Pharmaceutical has an Enterprise Value (EV) of 630.14B.
| EV / Sales | 2.33 |
| EV / EBITDA | 12.5 |
| EV / EBIT | 18.4 |
| EV / FCF | 24.87 |
Financial Position
The company has a current ratio of 2.47, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.47 |
| Quick Ratio | 1.93 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.21 |
| Debt / FCF | 0.41 |
| Interest Coverage | 204.33 |
Financial Efficiency
Return on Equity is 12.56% and Return on Invested Capital is 11.45%.
| Return on Equity | 12.56% |
| Return on Assets | 8.94% |
| Return on Invested Capital | 11.45% |
| Revenue Per Employee | $37.31M |
| Profits Per Employee | $4.26M |
| Employee Count | 7,259 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 2.43 |
Taxes
| Income Tax | 10.12B |
| Effective Tax Rate | 24.38% |
Stock Price Statistics
The stock price has increased by -1.95% in the last 52 weeks. The beta is -0.35, so Rohto Pharmaceutical's price volatility has been lower than the market average.
| Beta | -0.35 |
| 52-Week Price Change | -1.95% |
| 50-Day Moving Average | 20.61 |
| 200-Day Moving Average | 20.97 |
| Relative Strength Index (RSI) | 0.03 |
| Average Volume (20 Days) | 93 |
Income Statement
In the last 12 months, Rohto Pharmaceutical had revenue of 270.84B and earned 30.94B in profits. Earnings per share was 135.6.
| Revenue | 270.84B |
| Gross Profit | 157.29B |
| Operating Income | 40.05B |
| Net Income | 30.94B |
| EBITDA | 50.4B |
| EBIT | 41.71B |
| Earnings Per Share (EPS) | 135.6 |
Balance Sheet
The company has 89.21B in cash and 10.49B in debt, giving a net cash position of 78.72B.
| Cash & Cash Equivalents | 89.21B |
| Total Debt | 10.49B |
| Net Cash | 78.72B |
| Retained Earnings | 209.4B |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was 34.24B and capital expenditures -8.91B, giving a free cash flow of 25.33B.
| Operating Cash Flow | 34.24B |
| Capital Expenditures | -8.91B |
| Free Cash Flow | 25.33B |
| FCF Per Share | 111.04 |
Margins
Gross margin is 58.07%, with operating and profit margins of 14.79% and 11.42%.
| Gross Margin | 58.07% |
| Operating Margin | 14.79% |
| Pretax Margin | 15.33% |
| Profit Margin | 11.42% |
| EBITDA Margin | 18.61% |
| EBIT Margin | 14.79% |
| FCF Margin | 9.35% |
Dividends & Yields
RPHCF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 4.36% |
| FCF Yield | 3.57% |
Analyst Forecast
Currently there are no analyst rating for RPHCF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Dec 29, 2022. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 29, 2022 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |